Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk

Authors: B Frank, K Hemminki, M Wirtenberger, JL Bermejo, P Bugert, R Klaes, RK Schmutzler, B Wappenschmidt, CR Bartram, B Burwinkel

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Overexpression of the proto-oncogene ERBB2 (HER2/NEU) has been observed in 20–30% of breast cancers involving ligand-independent activation and more aggressive growth behaviour, reduced response to chemotherapy and hormonal therapy, as well as poor prognosis. Genetic alterations within ERBB2 have been shown to induce carcinogenesis and metastasis. …
Literature
1.
Frank B, et al: The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005, 26: 643-647. 10.1093/carcin/bgh342.CrossRefPubMed
Metadata
Title
The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk
Authors
B Frank
K Hemminki
M Wirtenberger
JL Bermejo
P Bugert
R Klaes
RK Schmutzler
B Wappenschmidt
CR Bartram
B Burwinkel
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1105

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Poster Presentation

Ex vivo isolation of adult stem cells from normal and tumour mouse mammary parenchyma

Poster Presentation

Screening for germline rearrangements in BRCA1 and BRCA2in Norwegian families with breast or breast/ovarian cancer

Poster Presentation

Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)

Oral Presentation

Genes, genomes, and cancer

Oral Presentation

Abstract withdrawn

Oral Presentation

Expression profiling as a prognostic and predictive factor in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits